LPAR1/LPA1/EDG-2 Antibody [Unconjugated]

Western blot shows lysates of Jurkat human acute T cell leukemia cell line, human brain (cerebellum) tissue, and human liver tissue (negative control). PVDF membrane was probed with 2 µg/mL of Goat Anti-Human LPAR1/LPA1/EDG-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF9963) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for LPAR1/LPA1/EDG-2 at approximately 48-51 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

miR-367 downregulates LPA1 expression. a Bioinformatics prediction of binding sites for miR-367 and LPA1. b Luminescence activity of LPA1 by dual luciferase reporter gene assay. c RIP assay detection of the binding of miR-367 and LPA1 to Ago2. d Detection of relative expression of LPA1 in cancer tissues and adjacent normal tissues by RT-qPCR. e Analysis of protein level of LPA1 in cancer and adjacent normal tissues by western blot analysis. f Statistical expression of protein level of LPA1. g Correlation analysis between miR-367 and LPA1. h RT-qPCR results of the relative expression level of LPA1 in each group of cells. i Western blot analysis of LPA1 protein levels in each group of cells. j Statistical protein expression level of LPA1. Measurement data were expressed as mean ± standard deviation. Data in compliance with normal distribution and homogeneity between two groups were compared using t test. Comparisons among multiple groups were conducted by one-way ANOVA followed by Tukey’s post hoc test. *p < 0.05 vs. normal tissues or cells; #p < 0.05 vs. Inhibitor NC The experiment was repeated three times independently Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33024414), licensed under a CC-BY license. Not internally tested by R&D Systems.

Low expression of LPA1 inhibits tumorigenic ability of ovarian cancer in nude mice. a Volume of mice tumor. b Weight of mice tumor. c RT-qPCR detection results of mRNA levels of related factors in tumor tissues. d Western blot analysis of the protein levels of related factors in tumor tissues. e Statistical graph of protein levels of related factors. f Immunohistochemistry for detecting CD34 expression (200×). Measurement data were expressed as mean ± standard deviation. Data in compliance with normal distribution and homogeneity between two groups were compared using t test. Comparisons among multiple groups were conducted by one-way ANOVA followed by Tukey’s post hoc test. Statistics of tumor volume at different time points was analyzed using repeated measures ANOVA. *p < 0.05 vs. normal tissues or cells. The experiment was repeated three times independently Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33024414), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated

LPAR1/LPA1/EDG-2 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human LPAR-1 CD33 protein containing the sequences for the four extracellular domains, amino acids (aa) 1-50, aa112-125, aa190-205 and aa281-294
  Accession # Q92633
• Specificity: Detects human LPAR-1/LPA₁/EDG-2 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LPAR1/LPA1/EDG-2 Antibody [Unconjugated]

• EDG2
• edg-2
• EDG2Lysophosphatidic acid receptor Edg-2
• endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor2,
• GPCR26
• GPR26
• LPA receptor 1
• LPA1
• LPA-1
• LPA1vzg-1
• LPAR1
• lysophosphatidic acid receptor 1
• Mrec1.3
• rec.1.3
• ventricular zone gene 1
• VZG1
• vzg-1

Background

Lysophosphatidic acid receptor 1, LPAR1, also known as EDG-2, is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). EDG molecules are G protein-coupled receptors that bind plasma lysophospholipids. The EDG family consists of two subfamilies; the S1P (sphingosine-1-phosphate) subfamily consisting of EDG-1, 3, 5, 6, and 8, and the LPA subfamily that contains EDG-2, 4 and 7. The S1P family regulates essential cellular processes such as proliferation, migration, cytoskeletal organization, and differentiation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LPAR1/LPA1/EDG-2 Antibody (AF9963)(1)

Publication using AF9963

• Q Zheng, X Dai, W Fang, Y Zheng, J Zhang, Y Liu, D Gu Overexpression of microRNA-367 inhibits angiogenesis in ovarian cancer by downregulating the expression of LPA1 Cancer Cell Int, 2020-10-02;20(0):476. 2020-10-02 [PMID: 33024414] (IHC, Western Blot, Human, Mouse)

Bioinformatics

• Uniprot:
  • Q92633()